Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
Read more at MarketWatch
Topics
-
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.CNBC - 3h -
Chipmakers are finding that good earnings aren't enough to please Wall Street
After investors poured into semiconductor stocks last year, expectations are high, and companies are having trouble making Wall Street happy.CNBC - 2d -
These accounts can be the 'worst possible asset’ for retirement, expert says. Here's why
Many investors don't plan for future taxes when contributing to traditional IRAs. Here are the key things to know.CNBC - 2d -
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.The New York Times - 4d -
Best 7 Coffee Makers (2025): Drip Is Drippin'
The old-fashioned drip coffee maker has come a long way. Our favorite machines here can turn your barista into a stranger.Wired - 3d -
Death of a Unicorn review – goofy eat-the-rich satire isn’t fun enough
SXSW film festival: Jenna Ortega, Paul Rudd and Richard E Grant lead a wasted cast in this silly and exasperating mishmash of comedy and gore. The unicorn has been a staple of folk mythology for ...The Guardian - 23h -
Hikma races to launch generic versions of blockbuster obesity drugs
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next yearFinancial Times - 1d -
The M3 iPad Air Is Unsurprisingly Good
The iPad Air with M3 isn’t much different, but that shouldn’t surprise you.Inc. - 2h -
More couples are choosing lab-grown diamonds over natural stones for engagement rings. Here’s why
Lab-grown diamonds outpace natural stones when it comes to engagement rings. Here’s why, and what to consider when shopping.CNBC - 4h
More from MarketWatch
-
Super Micro’s stock has its doubters, but it just got a vote of confidence
Super Micro is a “show-me story,” says a Rosenblatt analyst, but he sees room for gross margins to expand as the company sells more to enterprise customers.MarketWatch - 20m -
How buyers are winning bidding wars in a market where homes are selling for $620,000 over ask
The spring home-buying season could be bruising in this region, where bidding wars are alive and well.MarketWatch - 29m -
LinkedIn co-founder has known Elon Musk for years. Here’s what he says Americans don’t understand about the Tesla CEO.
Elon Musk takes a hammer-and-nail approach to everything, LinkedIn co-founder Reid Hoffman says.MarketWatch - 1h -
Redfin’s stock soars on buyout deal with Rocket Cos. that looks to speed up home buying
Rocket wants to be a one-stop shop for the home-buying process.MarketWatch - 1h -
Do older adults understand healthcare risks?
Misperceptions of long-term care needs and costs are cause for concernMarketWatch - 1h
More in Business
-
Oil tanker hit by container ship in North Sea
Helicopters, lifeboats and firefighters sent to location off coast of HumbersideFinancial Times - 11m -
Bitcoin briefly falls under $80,000 on heightened recession fears
Bitcoin briefly slipped under the $80,000 level Monday, dragged by the continued selling pressure in the equities market.CNBC - 17m -
Super Micro’s stock has its doubters, but it just got a vote of confidence
Super Micro is a “show-me story,” says a Rosenblatt analyst, but he sees room for gross margins to expand as the company sells more to enterprise customers.MarketWatch - 20m -
Is X Down? Users Report Intermittent Outages
Several waves of reported outages affected the social media site, formerly known as Twitter, on Monday.The New York Times - 21m -
Barclays chair has shifted view on Staley’s relationship with Epstein, court hears
Nigel Higgins tells court that information which has come to light ‘paints a different picture’ of nature of tiesFinancial Times - 24m